The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the listing of natalizumab (Tysabri®) pre-filled syringe for subcutaneous (under the skin) injection on the Pharmaceutical Benefit Scheme (PBS).
CEO Rohan Greenland shares an update on The May 50K, thanking participants for their significant contributions. He then unveils MS Australia’s plans to champion the invaluable role of MS Nurses on World MS Day.
Australian scientists have found new immune-suppressing molecules produced in response to UV exposure that may explain how UV protects from multiple sclerosis.
Clinical Trials Day is an opportunity to express our gratitude to the researchers, clinicians, and nurses who dedicate their lives to advancing medical knowledge and improving patient care. We thank them for their tireless efforts in conducting ground-breaking research and for their commitment to finding new and innovative treatments. Their work is essential for improving health outcomes for people around the world, and we are grateful for their dedication and contributions.
Developing and maintaining close friendships can be challenging for individuals with chronic conditions, like MS. Normative expectations about physical ability combined with the emotional and physical work required to maintain social connections can hinder the continuation of friendships.
Dr. Phu’s MS Australia-funded research focuses on physiotherapy interventions to improve impaired functions caused by MS. His current project aims to develop personalised exercise programs with assistive devices to enhance walking abilities in people with MS. These advancements will be implemented at the new MS Plus Wellbeing Centres through Project Wellbeing.
The 2023-24 Federal Budget was delivered on 9 May 2023. MS Australia’s analysis of this Budget is through the lens of the two areas of fundamental need for people living with MS.
People with MS are helping us build the evidence for better government MS support.
CEO Rohan Greenland talks about the world’s first multi-arm, multi-stage trial for progressive MS named ‘OCTOPUS’, which recently launched in the UK and the hope that in time Australia will be able to link up with this globally significant ‘mega trial’ with our own trial sites.
